Filed in archive
Diagnostics
by Gloria Gamat on May 18, 2006
Several studies presented at the meeting evaluated the potential use of the CINtec® p16INK4a-based immunocytochemistry protocol on cervical cytology preparations.
The results from these studies indicate the high potential of p16INK4a-based tests being developed into efficient diagnostic tools for the triage of abnormal Pap cytology results.
p16INK4a - a biomarker central to diagnostic and screening technologies is being developed by mtm Laboratories for cervical cancer.
Cervical cancer being the second most common cancer in women can be prevented 10o% when detected at the early stage. But current screening technologies and diagnostics for cervical cancer have limitations; they have a high degree of subjectivity and do not actually detect direct disease markers.
This is where mtm Laborataories AG come in by developing a family of screening and diagnostic technologies based on the p16INK4a biomarker which promises extreme precision, giving confident and accurate early diagnosis of cervical cancer.
Source: PR Newswire
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/22245
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for p16INK4a, New Biomarker for Cervical Cancer Screening and Diagnosis:
|
Rating: 8.67 out of 6 vote(s) cast.
|
Response from:
Dr.Than Than Htwe
(01/18/07 10:50pm)
very interesting
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
